The role of pathogen infections in the development and progression of autoimmune liver diseases

Haiping ZHANG; Huiping YAN; Dexi CHEN; Yingmin MA

doi:10.3969/j.issn.1001-5256.2022.04.004

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 754-758

PDF( 1912 KB)

The role of pathogen infections in the development and progression of autoimmune liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.04.004

Center of Clinical Laboratory, Beijing YouAn Hospital, Capital Medical University & Beijing Institute of Hepatology, Beijing 100069, China

Research funding:

Pilot Project of Public Welfare Development and Reform of Beijing Municipal Medical Research Institutes (Jingyiyan 2021-10);

Young and Middle-aged Talent Incubation Project in the Hospital of Beijing YouAn Hospital, Capital Medical University, 2021 (Youth Innovation) (YNKTQN2021004)

More Information

Corresponding author: YAN Huipng, yhp503@126.com(ORCID: 0000-0002-1787-0067)
Received Date: 2022-01-04
Accepted Date: 2022-02-17
Published Date: 2022-04-20

Abstract

Abstract

The etiology and pathogenesis of autoimmune liver diseases has always been a hot area of research. Pathogen infections can elicit an autoimmune response and often become the key pathogenic factor of immune diseases. Based on the literature data and the author's clinical experience, this review will briefly introduce the role and influence of pathogen infections in the development and progression of autoimmune liver diseases from the aspects such as molecular mimicry mechanism, in order to further understand the pathogenesis of autoimmune liver diseases.
- Noxae,
- Autoimmune Liver Disease,
- Molecular Mimicry,
- Pathologic Processes

FullText(HTML)

References(40)

References

[1]	CZAJA AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions[J]. World J Gastroenterol, 2019, 25(45): 6579-6606. DOI: 10.3748/wjg.v25.i45.6579.
[2]	TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198.
[3]	ROWLEY D, JENKIN CR. Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity[J]. Nature, 1962, 193: 151-154. DOI: 10.1038/193151a0.
[4]	DAMIAN RT. Molecular mimicry in biological adaptation[J]. Science, 1965, 147(3660): 824. DOI: 10.1126/science.147.3660.824-b.
[5]	FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
[6]	AGMON-LEVIN N, PAZ Z, ISRAELI E, et al. Vaccines and autoimmunity[J]. Nat Rev Rheumatol, 2009, 5(11): 648-652. DOI: 10.1038/nrrheum.2009.196.
[7]	ANG CW, JACOBS BC, LAMAN JD. The Guillain-Barré syndrome: A true case of molecular mimicry[J]. Trends Immunol, 2004, 25(2): 61-66. DOI: 10.1016/j.it.2003.12.004.
[8]	KOGA M, GILBERT M, LI J, et al. Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies[J]. PLoS One, 2015, 10(4): e0124004. DOI: 10.1371/journal.pone.0124004.
[9]	KIRVAN CA, GALVIN JE, HILT S, et al. Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis[J]. J Cardiovasc Transl Res, 2014, 7(2): 172-181. DOI: 10.1007/s12265-013-9526-4.
[10]	ZHANG Y, XIAO M, ZHANG S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19[J]. N Engl J Med, 2020, 382(17): e38. DOI: 10.1056/NEJMc2007575.
[11]	MIELI-VERGANI G, VERGANI D, CZAJA AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18017. DOI: 10.1038/nrdp.2018.17.
[12]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[13]	ZACHOU K, RIGOPOULOU E, DALEKOS GN. Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease[J]. J Autoimmune Dis, 2004, 1(1): 2. DOI: 10.1186/1740-2557-1-2.
[14]	FERRI S, MURATORI L, LENZI M, et al. HCV and autoimmunity[J]. Curr Pharm Des, 2008, 14(17): 1678-1685. DOI: 10.2174/138161208784746824.
[15]	MURATORI P, MURATORI L, VERUCCHI G, et al. Non-organ-specific autoantibodies in children with chronic hepatitis C: Clinical significance and impact on interferon treatment[J]. Clin Infect Dis, 2003, 37(10): 1320-1326. DOI: 10.1086/379018.
[16]	HAN Y, YAN HP, LIAO HY, et al. Clinical value of anti-liver/kidney microsomal-1 antibody in patients with liver disease[J]. Chin J Hepatol, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010. 韩莹, 闫惠平, 廖慧钰, 等. 抗肝肾微粒体抗体在肝病患者中的临床意义评价[J]. 中华肝脏病杂志, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010.
[17]	MARCEAU G, LAPIERRE P, BÉLAND K, et al. LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry?[J]. Hepatology, 2005, 42(3): 675-682. DOI: 10.1002/hep.20816.
[18]	FERRI S, MURATORI L, QUARNETI C, et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C[J]. J Hepatol, 2009, 50(6): 1093-1101. DOI: 10.1016/j.jhep.2009.02.020.
[19]	GREGORIO GV, CHOUDHURI K, MA Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection[J]. Clin Exp Immunol, 2003, 133(3): 404-413. DOI: 10.1046/j.1365-2249.2003.02229.x.
[20]	VENTO S, GAROFANO T, DI PERRI G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals[J]. Lancet, 1991, 337(8751): 1183-1187. DOI: 10.1016/0140-6736(91)92858-y.
[21]	YAN HP, JIA JD. Autoimmune liver disease[M]. Beijing: People's Medical Publishing House, 2018. 闫惠平, 贾继东. 自身免疫性肝脏疾病[M]. 北京: 人民卫生出版社, 2018.
[22]	RIGOPOULOU EI, SMYK DS, MATTHEWS CE, et al. Epstein-barr virus as a trigger of autoimmune liver diseases[J]. Adv Virol, 2012, 2012: 987471. DOI: 10.1155/2012/987471.
[23]	CHRISTEN U, HINTERMANN E. Pathogens and autoimmune hepatitis[J]. Clin Exp Immunol, 2019, 195(1): 35-51. DOI: 10.1111/cei.13203.
[24]	ZELLOS A, SPOULOU V, ROMA-GIANNIKOU E, et al. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: Art of facts or an artifact?[J]. Ann Hepatol, 2013, 12(1): 147-151.
[25]	MANNS MP, GRIFFIN KJ, SULLIVAN KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450ⅡD6, a cytochrome P-450 monooxygenase[J]. J Clin Invest, 1991, 88(4): 1370-1378. DOI: 10.1172/JCI115443.
[26]	HAGEL S, BRUNS T, HERRMANN A, et al. Autoimmune hepatitis in an HIV-infected patient: An intriguing association[J]. Int J STD AIDS, 2012, 23(6): 448-450. DOI: 10.1258/ijsa.2009.009337.
[27]	FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
[28]	BURROUGHS AK, ROSENSTEIN IJ, EPSTEIN O, et al. Bacteriuria and primary biliary cirrhosis[J]. Gut, 1984, 25(2): 133-137. DOI: 10.1136/gut.25.2.133.
[29]	FLOREANI A, BASSENDINE MF, MITCHISON H, et al. No specific association between primary biliary cirrhosis and bacteriuria?[J]. J Hepatol, 1989, 8(2): 201-207. DOI: 10.1016/0168-8278(89)90008-1.
[30]	CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
[31]	GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42(5): 1194-1202. DOI: 10.1002/hep.20907.
[32]	PARIKH-PATEL A, GOLD EB, WORMAN H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states[J]. Hepatology, 2001, 33(1): 16-21. DOI: 10.1053/jhep.2001.21165.
[33]	PRINCE MI, DUCKER SJ, JAMES OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations[J]. Gut, 2010, 59(4): 508-512. DOI: 10.1136/gut.2009.184218.
[34]	CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
[35]	SHIMODA S, HARADA K, NIIRO H, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis[J]. Hepatology, 2011, 53(4): 1270-1281. DOI: 10.1002/hep.24194.
[36]	BJÖRKLAND A, FESTIN R, MENDEL-HARTVIG I, et al. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells[J]. Hepatology, 1991, 13(6): 1106-1111. DOI: 10.1002/hep.1840130617.
[37]	van de WATER J, ANSARI A, PRINDIVILLE T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis[J]. J Exp Med, 1995, 181(2): 723-733. DOI: 10.1084/jem.181.2.723.
[38]	FREDRICKSON JK, BALKWILL DL, DRAKE GR, et al. Aromatic-degrading Sphingomonas isolates from the deep subsurface[J]. Appl Environ Microbiol, 1995, 61(5): 1917-1922. DOI: 10.1128/aem.61.5.1917-1922.1995.
[39]	TAKEUCHI M, HAMANA K, HIRAISHI A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses[J]. Int J Syst Evol Microbiol, 2001, 51(Pt 4): 1405-1417. DOI: 10.1099/00207713-51-4-1405.
[40]	MANFREDO VIEIRA S, HILTENSPERGER M, KUMAR V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161. DOI: 10.1126/science.aar7201.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (600) PDF downloads(99)

The role of pathogen infections in the development and progression of autoimmune liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.04.004

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The role of pathogen infections in the development and progression of autoimmune liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.04.004

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content